semaglutide vs tirzepatide efficacy weight loss soul trial oral cardiovascular outcomes results 2024 nejm Cardiovascular Outcomes, Safety, and Tolerability With Oral Semaglutide: Insights for Managed Care SELECT Trial

We started with a clear plan so we could capture both the landmark randomized trials and the real-world studies that show how the drug performs beyond the clinic

For your patients 1 year of age and older with type 1 diabetes Tresiba (insulin degludec) provides proven A1C reduction with once-daily dosing 1 Efficacy and safety evaluated in adults with T1D Safety study in adults with T1D at increased risk of hypoglycemia Efficacy and safety evaluated in pediatric patients with T1D Safety study in pregnant women with type 1 diabetes As demonstrated in the BEGIN clinical trial program Tresiba offers proven A1C control 1 ADULTS WITH T1D Comparator mean change from baseline Insulin glargine U-100 + insulin aspart Baseline: 7.7% End of trial: 7.3% Reduction: 0.34% Primary endpoint in Study A: A1C reduction from baseline through Week 52

Participation in clinical trials designed to identify treatments that will further extend RFS and OS with less toxicity and shorter treatment schedules is an important option for all patients

Iron and B-vitamin intake often decreases when overall food intake decreases